Stability of sulforaphane for topical formulation

被引:49
|
作者
Franklin, Stephen J. [1 ]
Dickinson, Sally E. [2 ]
Karlage, Kelly L. [1 ]
Bowden, G. T. [3 ]
Myrdal, Paul B. [1 ]
机构
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] Univ Arizona, Ctr Canc, Dept Pharmacol, Tucson, AZ 85721 USA
[3] Univ Arizona, Ctr Canc, Dept Cellular & Mol Med, Tucson, AZ 85721 USA
关键词
Activator-protein-1; base catalysis; degradation; hydrolysis; in vivo; isothiocyanate; UVB; INDUCED ACTIVATOR PROTEIN-1; BROCCOLI SPROUT EXTRACTS; HAIRLESS MOUSE MODEL; PERILLYL ALCOHOL; SKIN-CANCER; INHIBITION; AP-1; CHEMOPREVENTION; EXPRESSION;
D O I
10.3109/03639045.2013.768634
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Context: Sulforaphane (SFN) is a natural compound that has been investigated as a chemopreventive agent. SFN has been shown to inhibit the activator-protein-1 (AP-1) transcription factor and may be effective for inhibition of ultraviolet (UV) induced skin carcinogenesis. This study was designed to investigate the stability of SFN as a function of pH, temperature and in various solvents and formulations. Materials and methods: Stability was analyzed using high-performance liquid chromatography. A potential lead formulation was identified and evaluated in vivo. Results: SFN was determined to undergo apparent first-order degradation kinetics for the conditions explored. It was observed that SFN undergoes base catalyzed degradation. Buffer species and solvent type impacts stability as well. SFN was found to be very sensitive to temperature with degradation rate changing by a factor of nearly 3.1 for every 10 degrees C change in temperature (at pH 4.0). SFN completely degraded after 30 days in a conventional pharmaceutical cream formulation. Improved stability was observed in organic formulation components. Stability studies were conducted on two nonaqueous topical formulations: a polyethylene glycol (PEG) ointment base and an organic oleaginous base. Conclusion: Topically applied SFN in the PEG base formulation significantly reduced AP-1 activation after UV stimulation in the skin of a transgenic mouse model, indicating that SFN in this formulation retains efficacy in vivo.
引用
收藏
页码:494 / 502
页数:9
相关论文
共 50 条
  • [21] Formulation, long-term physicochemical and microbiological stability of 15% topical resorcinol for hidradenitis suppurativa
    Cordero-Ramos, Jaime
    Merino-Bohorquez, Vicente
    Delgado-Valverde, Mercedes
    Barros-Tornay, Ruben
    Camean-Fenandez, Manuel
    Calleja-Hernandez, Miguel Angel
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (06) : 313 - 318
  • [22] Evaluation of stability and in vivo trans-corneal penetration of 1% topical calcium dobesilate formulation
    Nirmal, J.
    Velpandian, T.
    Ghose, S.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 181 - 181
  • [23] An approach to enhanced stability: Formulation and characterization of Solanum lycopersicum derived lycopene based topical emulgel
    Sohail, Muhammad
    Naveed, Akhtar
    Abdul, Rouf
    Gulfishan
    Khan, Hajji Muhammad Shoaib
    Khan, Hira
    SAUDI PHARMACEUTICAL JOURNAL, 2018, 26 (08) : 1170 - 1177
  • [24] Advances and challenges in serratiopeptidase topical formulation
    Patil, Sachin D.
    Wagdarikar, Manasi J.
    ANNALES PHARMACEUTIQUES FRANCAISES, 2024, 82 (06): : 966 - 979
  • [25] Formulation of Liposome for topical delivery of arbutin
    Ai-Hua Wen
    Min-Koo Choi
    Dae-Duk Kim
    Archives of Pharmacal Research, 2006, 29
  • [27] New formulation for topical treatment of onychomycoses
    Difonzo, Elisa M.
    Scarfi, Federica
    Galeone, Massimiliano
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2017, 152 (05): : 432 - 435
  • [28] FORMULATION REQUIREMENTS OF TOPICAL DELIVERY SYSTEMS
    GOLDEMBERG, RL
    DRUG DEVELOPMENT COMMUNICATIONS, 1976, 2 (01): : 43 - 62
  • [29] Effect of formulation on the topical delivery of α-tocopherol
    Rangarajan, M
    Zatz, JL
    JOURNAL OF COSMETIC SCIENCE, 2003, 54 (02) : 161 - 174
  • [30] DEVELOPMENT AND OPTIMIZATION OF A METHOTREXATE TOPICAL FORMULATION
    HWANG, GC
    LIN, AY
    CHEN, W
    SHARPE, RJ
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1995, 21 (17) : 1941 - 1952